StockData

BioLineRx vs MediciNova

BLRX and MNOV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BLRX and MNOV compare

MediciNova scores higher on the StockData Score (7 against 3 for BioLineRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBLRXMNOV
Size and price
Market cap–$66.0M
Share price$1.12$1.34
Change, 1 year−65.3%−13.5%
Change, 5 years−98.9%−58.4%
Beta (5Y)1.56−0.00
Employees206
StockData Score
Total score37 (better)
Valuation score01 (better)
Growth score1 (better)0
Performance score01 (better)
Health score25 (better)
Dividend score00
Valuation
P/S–71.7×
P/B–1.8×
FCF yield–−13.8%
Growth
Revenue growth (TTM)−95.9%–
Profitability
Gross margin80.5%–
Operating margin−872% (better)−1287%
Net margin–−1168%
FCF margin−686% (better)−991%
Return on equity–−25.6%
Return on invested capital−59.7% (better)−76.6%
Financial health
Debt / equity0.33 (better)0.00
Interest coverage−8.0×–
Current ratio1.208.75 (better)
Altman Z-score–−3.11
Piotroski F-score–2
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.00%10.5%
Held by insiders0.39%12.8%
Insider net buying, 12 months–−$1.7M
Short interest, % of float–0.66%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.